Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Bluebird bio, Inc.    BLUE

BLUEBIRD BIO, INC.

(BLUE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo bluebird bio, Inc.
bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD). Its programs in oncology focuses on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. It also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.
Sales per Business
20192020Delta
USD (in Million)%USD (in Million)%
Gene Therapy Products44.67100%250.73100% +461.25%
Sales per region
20192020Delta
USD (in Million)%USD (in Million)%
United States44.67100%250.73100% +461.25%
Managers and Directors
NameAgeSinceTitle
Nick Leschly472010President, Chief Executive Officer & Director
William Denise Baird482021Chief Financial & Accounting Officer
Daniel Lynch612011Chairman
David M. Davidson, Dr.562012Chief Medical Officer
Philip D. Gregory, Dr.492015Chief Scientific Officer
Derek Adams, Dr.-2017Chief Technology & Manufacturing Officer
Mohammed Asmal, Dr.-2017Vice President-Clinical Development
Jason F. Cole472019Chief Operating & Legal Officer
Wendy L. Dixon, Dr.642013Independent Director
Mark L. Vachon612014Independent Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 67,141,044 66,040,362 98.4% 0 0.0% 98.4%
Shareholders
NameEquities%
Capital Research & Management Co. (Global Investors) 8,128,284 12.2%
The Vanguard Group, Inc. 6,463,232 9.74%
Wellington Management Co. LLP 5,349,165 8.06%
Sands Capital Management LLC 3,163,651 4.77%
Capital Research & Management Co. (World Investors) 3,127,163 4.71%
RBC Global Asset Management (UK) Ltd. 3,089,910 4.66%
SSgA Funds Management, Inc. 2,290,862 3.45%
BlackRock Fund Advisors 1,787,002 2.69%
Credit Suisse Securities (USA) LLC (Broker) 1,508,476 2.27%
Victory Capital Management, Inc. (Investment Management) 1,458,151 2.20%
Company contact information
bluebird bio, Inc.
60 Binney Street
Cambridge, MA 02142

Phone : +1.339.499.9300
Web : http://www.bluebirdbio.com
Sector Bio Therapeutic Drugs